NCT01357161

Who might be able to join this trial:

• You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer (confirmed by a tissue sample), and it is not a low-grade or borderline type.
• Your cancer has come back or gotten worse after receiving chemotherapy that included paclitaxel and a platinum-based drug.
• Your cancer returned or progressed 6 months or more after finishing your most recent platinum-based chemotherapy (known as "platinum-sensitive" disease).
• Your cancer can be measured on scans or imaging.
• A tumour tissue sample is available from your diagnosis or treatment.
• You are generally well enough to carry out light activity and care for yourself (confirm with trial site).
• Your heart, liver, kidneys, and other organs are working well enough (confirm with trial site).

Who may not be able to join:

• You are pregnant or planning to become pregnant during the study.
• You have taken part in another clinical trial or used an experimental drug or device within the past 28 days.
• Your cancer has spread to the brain or spinal fluid, or you have a primary brain tumour.
• You have a known allergy or medical reason why you cannot take paclitaxel, carboplatin, or adavosertib, or related substances used in their preparation.
• You take certain medications that affect how the body processes a specific liver enzyme (CYP3A4) — confirm with the trial site which medications apply.
• You have nerve damage (such as numbness or tingling) of a moderate level or worse from previous treatment.
• You have a known mental health condition or substance use disorder.
• You regularly use illegal drugs, or have had a problem with drugs or alcohol within the past year.
• You are HIV positive.
• You have active Hepatitis B or Hepatitis C.
• You have a build-up of fluid in your abdomen or around your lungs that is causing symptoms.
• Your personal or family medical history suggests a rare inherited condition called Li-Fraumeni Syndrome (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.